A second generation genetically-engineered cell-based drug delivery system, referred to as apoptotic-induced drug delivery (AIDD), was developed using endothelial cells (ECs) that undergo apoptosis upon binding of vascular endothelial growth factor (VEGF) to a Flk-1:Fas fusion protein (FF). This new AIDD was redesigned using mouse brain derived ECs, bEnd3 cells, and an adenovirus vector in order to enhance and control the expression of FF. The FF was tagged with a HA epitope (FFHA) and designed to be coexpressed with green fluorescence protein (GFP) by the regulation of cytomegalovirus promoters in the adenovirus vector. bEnd3 cells showed favorable coexpression of FFHA and GFP consistent with the multiplicity of infection of the adenovirus. Immunofluorescence analysis demonstrated that FFHA was localized at the plasma membrane, whereas GFP was predominantly located in the cytoplasm of ECs. Cell death was induced by VEGF, but not by platelet derived growth factor or fibroblast growth factor in a dose-dependent manner (range 2-20 ng/ml), and revealed caspase-dependent apoptotic profiles. The FFHA expressing bEnd3 cells underwent apoptosis when cocultured with a glioma cell (SF188V þ ) line able to overexpress VEGF. The combined data indicated that the FFHA adenovirus system can induce apoptotic signaling in ECs in response to VEGF, and thus, is an instrumental modification to the development of AIDD. Oncogene (2006 Oncogene ( ) 25, 954-958. doi:10.1038 published online 10 October 2005 Keywords: endothelial cells; drug delivery; adenovirus; VEGF; apoptosis The delivery of drugs to specific sites within the human body for the treatment of localized diseases with a minimum of adverse side effects represents one of the greatest challenges in chemotherapy. Numerous types of biodegradable drug carriers, such as liposomes, various colloid systems and macromolecule-drug conjugates have been designed to achieve controlled drug release and organ-specific targeting (Dass, 2002; ten Tije et al., 2003) . We have taken a fundamentally different approach to tumor targeting by using drugloaded genetically engineered endothelial cells (ECs) that are designed to apoptose upon binding and activation of a growth factor, which can promote delivery of drugs. This system, designated apoptoticinduced drug delivery (AIDD), takes advantage of many properties of ECs, which includes their relative resistance to anticancer drugs, their ability to maintain transgene expression and their potential to localize at active sites in tumor neovascularization (Scappaticci, 2002) . Since vascular endothelial growth factor (VEGF) expression has been shown to be upregulated in many tumor types including brain tumors (Berkman et al., 1993; Plate et al., 1994) , we designed a fusion protein to be expressed on ECs that consisted of the extracellular domain of the VEGF receptor (Flk-1/KDR) and the transmembrane and intracellular domain of the cell death protein (Fas) (designated FF). Activation of FF by VEGF could initiate an apoptotic signal within the ECs exploiting tumor-specific events of high VEGF secretion. The apoptotic ECs, preloaded with an anticancer drug, are able to deliver drugs by enhanced drug transport through the permeable apoptotic membrane and phagocytosis by tumor cells, mechanisms we identified previously (Ma and Gallo, 1998a; Ma et al., 2002) . These latter studies that utilized bovine artery ECs loaded with paclitaxel demonstrated superior tumor growth inhibition following intratumoral injection in a scid mouse tumor model (Ma et al., 2002) . Favorable antitumor activity was also seen in this same animal model when the ECs were administered intravenously; however, the effect was not as pronounced as when the ECs were given intratumorally, and could be attributed to a limitation of ECs to target or home to tumors. This latter problem may, in part, be overcome if the ECs are derived from the tissue in which the tumor resides or progenitor cells, for example, circulating endothelial cells and mesenchymal progenitor cells (Pereboeva et al., 2003; Le Ricousse-Roussanne et al., 2004) . Given this possibility and our interest to develop AIDD for brain tumors, the current study utilized mouse brain derived ECs, bEnd3 as a platform to exploit genetically-modified ECs using an adenoviral system. Figure 1 shows a schematic representation of nonreplicative adenovirus constructs utilized in this study. In order to distinguish FF protein from endogenous Flk-1 and Fas in cells, the hemagglutinine (HA) epitope tag sequence was flanked at the carboxyl terminus of the FF protein, resulting in a fusion protein, HA epitope (FFHA), driven by the cytomegalovirus promoter (CMV) promoter in the adenovirus vector. AdGFP-FFHA was designed to coexpress both the FFHA and green fluorescence protein (GFP) proteins under the tandem repeated two independent cis CMV promoters. Ad-FFHA2 possesses two sets of the CMV promoter and FFHA, whereas Ad-GFP possesses only the cDNA for GFP and was utilized as a control adenovirus in this study. Actual infectious titer of the adenovirus was increased over 5 Â 10 9 plaque forming unit (PFU)/ml by CsCl-gradient ultra centrifugation. bEnd3 has been utilized as an in vitro model for the blood-brain barrier, and to analyse VEGF-mediated cell migration and signal transduction (Hallmann et al., 2000; Soga et al., 2001) . In order to assess bEnd3 cells with regard to the expression of adenoviral transgenes, bEnd3 cells were infected with a tenfold range of multiplicity of infection (moi ¼ 33-330) of adenoviruses; Ad-GFP, AdGFP-FFHA or Ad-FFHA2, and herein referred to as Ad-GFP/bEnd3, AdGFP-FFHA/bEnd3 or Ad-FFHA2/bEnd3, respectively. Figure 2a shows that the expression of FFHA and GFP proteins in bEnd3 cells is well-correlated with the adenovirus titer. AdGFP-FFHA/bEnd3 or Ad-GFP/bEnd3 revealed Figure 1 Schematic representation of the adenovirus constructs. DE1 and DE3, deletion of the early viral gene transcription units E1 and E3; RITR and LITR, right and left inverted terminal repeat, respectively; CMV, cytomegalovirus promoter; PA, polyadenylation signal. In order to add the HA epitope tag sequence to the carboxyl terminus of the FF protein, a double stranded linker cDNA encoding HA, 5 0 -AATTCTACCCTTATGATGTGCCA-GATTATGCCTCTGAAAATCACTAGTGC-3 0 and 5 0 -GGCCG CACTAGTGATTTTCAGAGGCATAATCTGGCACATCATA AGGGTAG-3 0 was replaced with the region between EcoRI and NotI sites in the pcDNA3-FF (Ma et al., 2002) and the resulting construct was designated as pcDNA3-FFHA. All of adenovirus experiments were performed essentially as described previously (He et al., 1998; Wrede et al., 2002) . In order to construct AdGFP-FFHA recombinant, the region of CMV promoter and FFHA in pcDNA3-FFHA was excised from pcDNA3-FFHA by digestion with the restriction enzymes, BglII and NotI, and inserted into the multi-cloning site of the shuttle vector pAdTrack-CMV. The resulting clone was linearized with PmeI and combined with pAdEasy for the recombination in Escherichia coli strain BJ5183 (QBiogene). In order to construct Ad-FFHA2, the cDNA encoding FFHA was cloned into AgeI sites of pAdTrack-CMV followed by the insertion of the CMV promoter and FFHA coding region into the multicloning sites of pAdTrack-CMV. Ad-GFP was constructed by recombination between pAdTrack-CMV and pAdEasy. PFU is defined as the number of plaques and/or cells expressing GFP in 1 Â 10 6 Ad293 cells (Stratagene) in a total volume of 1 ml of media after the incubation with the adenovirus at 371C for 1 h. 5 cells/well) were infected with various titers of the adenovirus as specified in the figure. Following a 24 h incubation, a total cell lysate was prepared as described in Mitsuuchi et al. (1998) and subjected to 4-12% gradient polyacrylamide gels electrophoresis followed by the electro transfer to Immobilon-P membrane (Millipore Co.). Western blot analysis was performed by standard method with antibodies anti-HA and anti-GFP to detect FFHA and GFP, respectively. Anti-actin antibody was utilized to evaluate equal loading of each sample on the gel. The immunocomplexes on the membrane were visualized by the enhanced chemiluminescence reagent (PerkinElmer Life Sciences Inc.). (b) Histogram of FACS analysis. bEnd3 cells (2 Â 10 6 cells) were infected with 10 7 , 3 Â 10 7 , or 10 8 PFU/ml of AdGFP-FFHA followed by a 24 h incubation. The cells were collected in phosphate-buffered saline containing 0.5% fetal bovine serum and fixed with 75% ice-cold ethanol. Following washings, cells were monitored by measuring the percentage of positive GFP expressing cells as well as by determining the relative amount of intracellular GFP. FACS analysis was performed by using a Becton Dickinson FACScalibur and Cell QuestPro software. The percent positive for each of the infected bEnd3 cells was calculated using a marker M1 that displayed a positive background of 0.7% of gated cells for the uninfected control cells (white peak). All of the gates and settings were kept constant throughout the entire study. The x axis is the log of GFP fluorescence and the y axis is the number of cells with that fluorescence value. bEnd3 cells infected with 10 7 , 3 Â 10 7 , and 10 7 PFU/ml were colored as light, middle, and dark gray areas, respectively. (c) Lasting expression of FFHA and GFP in bEnd3 cells. Following the infection with AdGFP-FFHA, the cell lysates were prepared at the time indicated and subjected to the immunoblot analysis as described above À indicates the control cell lysate prepared from noninfected bEnd3.
Induce apoptosis by vascular endothelial growth factor Y Mitsuuchi et al identical expression level of GFP when the same amounts of adenoviruses was used, whereas the expression of FFHA was significantly increased, as anticipated, by Ad-FFHA2 infection in comparison to by AdGFP-FFHA under the identical infection condition (Figure 2a) . Fluorescence-activated cell sorting (FACS) analysis (Figure 2b ) was completed with bEnd3 cells infected with different titers of adenovirus. The cells were sorted by the percentage of positive GFP expressing cells based on green intensity relative to the uninfected control culture. Over 97% cells showed GFP expression following the infection with 3 Â 10 7 PFU/ml adenovirus and the intensity of GFP increased with an increase in the infection titer, analogous to the protein expression analysis in Figure 2a . The expression of both FFHA and GFP proteins were detected within 24 h following infection and lasted for at least 4 days (Figure 2c) .
It has been shown that Fas must be oligomerized for activation at the surface of cells and the cytoplasmic domain of Fas is necessary and sufficient to transduce the apoptotic signal (Itoh and Nagata, 1993; Wallach et al., 1999) . Immunofluorescence analysis was carried out to evaluate the localization of FFHA protein expressed in bEnd3 cells, and revealed that FFHA and GFP proteins were coexpressed in AdGFP-FFHA/ bEnd3 cells and, as expected, primarily localized at the plasma membrane and cytoplasm, respectively (Figure 3) .
Fas receptor-mediated apoptosis is highlighted by activation of caspases for proteolytic cleavage, the formation of plasma membrane blebs and nuclear and cell fragmentations. The apoptotic process does not require RNA or protein synthesis and can be either enhanced or inhibited by cycloheximide or the caspase inhibitor Z-VAD-fmk (ZVAD), respectively (Ni et al., 1994) . We investigated the nature of apoptosis in Ad-FFHA2/bEnd3, Ad-GFP/bEnd3, and parental bEnd3 cells by determining caspase-3 and -7 activities following VEGF stimulation. In the control bEnd3 and Ad-GFP/ bEnd3 cells the caspases were not activated following VEGF stimulation, whereas significant activation occurred in Ad-FFHA2/bEnd3 cells treated with VEGF. In addition, apoptotic cell death in Ad-FFHA2/bEnd3 was enhanced by cycloheximide, and conversely, almost completely blocked by ZVAD (Figure 4b ). These data indicate that Ad-FFHA2/bEnd3 cells underwent apoptosis through Fas death domain-mediated signaling initiated by VEGF.
VEGF activates various mitotic and cell survival signal transduction pathways, such as extracellular signal-regulated kinases and phosphatidylinositol 3-kinase-AKT signaling pathway, which antagonizes apoptosis and plays a role in vascular homeostasis in ECs (Dejana, 2004) . Therefore, it was of interest to determine the specificity and susceptibility of the bEnd3 cells expressing FFHA to undergo apoptosis in response to VEGF. Parental bEnd3 cells, Ad-GFP/bEnd3 or Ad-FFHA2/bEnd3 were incubated for 48 h in the absence or presence of various concentration of VEGF, and subsequently, the detached cells were collected and counted. Although the basal level of cell death was slightly increased by the adenovirus infection compared to the noninfected parental cells, the parental and Ad-GFP/bEnd3 cells did not show appreciable cell death by VEGF treatment (Figure 5a ). In contrast, cell death was significantly increased in the Ad-FFHA2/bEnd3 by . Indirect immunofluorescence analysis was performed as described previously (Mitsuuchi et al., 1998) . FFHA was visualized by using Anti-HA antibody (1 mg/ml) and Cy3-conjugated anti-mouse antibody (1.5 mg/ml) and nuclei were counter stained with 1% diamidino-2-phenylindole (DAPI; Sigma). Fluorescence images were captured by a cooled (À351C) charge-coupled device camera, Photometrics Quantix. Figure 4 FFHA induces caspase-dependent apoptosis. (a) bEnd3, Ad-GFP/bEnd3, and Ad-FFHA2/bEnd3 cells cultured in microplates (2000 cells/well) were treated with VEGF (10 ng/ml) for 18 h, followed by the apoptosis assay utilizing a caspases-3 and -7 specific luminogenic substrate (Promega). Results represent* -fold increase in activity over untreated bEnd3 cells with the mean7s.e. of three experiments. (b) Ad-FFHA2/bEnd3 cells were treated with VEGF (2 ng/ml) in the absence or presence of dimethylsulfoxide (DMSO), 1 mg/ml cycloheximide (CHX; Sigma) or 20 mM ZVAD (Calbiochem) for 48 h at 371C. Cell death was counted by TdTmediated dUTP Nick End Labelling. Data are shown as means7s.e. of three determinations. * and ** indicate Po0.05 and o0.01, respectively.
Induce apoptosis by vascular endothelial growth factor Y Mitsuuchi et al VEGF in a dose-dependent manner (Figure 5a ), and thus, VEGF could not sustain cell survival as in other ECs.
As shown in Figure 2a , FFHA expression level was enhanced to a great extent by Ad-FFHA2 adenovirus compared to by AdGFP-FFHA under the same infection condition. Analogous conditions were used to evaluate the susceptibility of Ad-FFHA2/bEnd3 and AdGFP-FFHA/bEnd3 cells to undergo apoptosis following VEGF treatment. Nonspecific cell death prior to VEGF treatment did not show significant differences between cells infected with either adenovirus, whereas Ad-FFHA2/bEnd3 showed elevated susceptibility to VEGF compared to AdGFP-FFHA/bEnd3 (Figure 5b ). In addition, using a growth factor specificity test (Figure 5c ), only VEGF treatment caused significant cell death in cells expressing FFHA. These data indicated that FFHA expression by the adenoviruses, AdGFP-FFHA, or Ad-FFHA2, conferred bEnd3 cells to undergo VEGF-dependent cell death, and the susceptibility and sensitivity of cell death induction correlated with FFHA expression level and VEGF stimulation.
We previously established a tumorigenic human glioma cell line, SF188V þ , which overexpresses VEGF (Ma et al., 1998b) . This expression pattern was confirmed for the current study as seen in Figure 6a , in which SF188V þ cells show appreciable secretion of VEGF whereas SF188VÀ cells do not. In order to establish an animal tumor model to evaluate AIDD, we performed cell overlay assays with either SF188V þ or SF188VÀ cells and Ad-GFP/bEnd3 or AdGFP-FFHA/ bEnd3 to determine whether the modified bEnd3 cells could undergo cell death when exposed to SF188V þ cells. Fluorescence microscopic analysis revealed that cell death was not observed in Ad-GFP/bEnd3 cells cocultured either with SF188VÀ or SF188V þ cells, whereas >90% of AdGFP-FFHA/bEnd3 died by coculture with SF188V þ cells, but not with SF188VÀ cells (Figure 6b ). Over 50% of the AdGFP/bEnd3 cells failed cell adhesion and showed apoptotic morphology on SF188V þ cells after a 24 h incubation (data not shown). 8 PFU/ml of either AdGFP-FFHA or Ad-FFHA2 were incubated with the culture medium containing 10 ng/ml VEGF for 48 h. Cell death was measured as described above. Data are shown as means7s.e. of three determinations. * indicates Po0.05. (c) Growth factor specificity test. Ad-GFP/bEnd3 and AdGFP-FFHA/bEnd3 cells were incubated with the culture medium in the absence or presence of growth factors for 48 h. N, V, F, and P indicate no growth factor, VEGF (20 ng/ml), fibroblast growth factor (Sigma) (50 ng/ ml) and platelet derived growth factor (cell signaling) (20 ng/ml), respectively. The number of dead cells was counted as described above. Figure 6 (a) Expression of VEGF in SF188VÀ and SF188V þ cell lines. The condition medium was prepared as described previously (Ma et al., 1998b) . VEGF in cell lysate (30 mg) and the condition medium was analysed by Western blot analysis with anti-VEGF antibody (0.2 mg/ml) (Santa Cruz Biotechnology). Lanes 1 and 2 are cell lysates prepared from SF188VÀ and SF188V þ , respectively, and lanes 3 and 4 are condition medium prepared from SF188VÀ and SF188V þ , respectively. (b) In vitro overlay assays. SF188V þ (panels 1 and 3) and SF188VÀ (panels 2 and 4) cells were cultured in glass slide chambers (50 000 cells/slot) for 24 h, followed by coculture with Ad-GFP/bEnd3 (panels 1 and 2) or AdGFP-FFHA/bEnd3 (panels 3 and 4) cells (5000 cells/slot) for 24-48 h. The cells were fixed on the glass slides with 3.5% performaldehyde and the nuclei were counter stained with 1% DAPI. Phase and fluorescence images were captured as described above. Upper and lower in each panel are images of GFP converted to gray scale showing the bEnd3 cells overlaid and the merged images of GFP and DAPI, respectively. Arrows indicate apoptotic bEnd3 cells showing shrinkages and/or membrane blebs.
Various mammalian cells, such as progenitor cells, ECs, fibroblasts, mesothelial cells, and erythrocytes have been proposed as vehicles to deliver genes, chemotherapeutic agents and enzymes with the potential for overcoming physiological and biochemical barriers. AIDD is a unique cell carrier on a number of counts, and the only system designed to enhance drug delivery using apoptosis as a triggering mechanism. In our previous study (Ma et al., 2002) , bovine pulmonary arterial ECs, CCL209, were genetically modified by stable transfection of a pEGFP-N3/flk-1:fas plasmid harboring a cDNA encoding a fusion protein of FF:EGFP. However, we noticed that the modified CCL209 cells had reduced cell proliferation compared to parental CCL209 cells and could not be used for studying AIDD after several passages, most likely due to continuous overexpression of the death activation domain (Chinnaiyan et al., 1995) . The adenovirus system, we established in this study showed constructive results and achieved transient high expression of FFHA protein in bEnd3 cells. The prolonged expression of FFHA did not result in significant cell death for at least up to 4 days. FFHA protein expressed from the adenoviral vector localized at the plasma membrane and induced apoptosis by VEGF stimulation in a dosedependent manner. Our data also indicated that the expression level of FFHA in the ECs has to be optimized, as the susceptibility of cell death induced by VEGF stimulation was related to the expression level of FFHA in bEnd3 cells. FFHA appeared to induce caspase-dependent apoptosis in response to VEGF in bEnd3 cells, whereas parental bEnd3 cells increased cell growth rate by 1.5 when exposed to VEGF in culture (data not shown). These opposing actions indicate a pivotal role of VEGF in cell proliferation or death, and therefore, precise control of FFHA expression is critical to ensure that apoptotic signaling dominates survival signaling in the ECs. There have been alternate DNA vector approaches able to express FF fusion proteins (Quinn et al., 2001; Carpenito et al., 2002; Ma et al., 2002) . In each case, the sources of the cDNA, the sequences of the FF protein and expression vectors were different, and consequently, so was the susceptibility to VEGF-induced apoptosis. Based on the appreciable control of FFHA expression and capability of apoptosis induction afforded by the Ad-FFHA2 adenovirus it will be preferred vector system in future studies to assess AIDD.
There are many variables that will have to be analysed and overcome as AIDD systems are developed. These include the ability of ECs to target tumors upon systemic administration and the ability of drugs preloaded in ECs to be released at the tumor in sufficient quantities. We have currently focused on mouse brain derived ECs, however, other cell types, namely bone marrow derived endothelial progenitor cells and hematopoietic stem cells may have a greater potential to target tumors upon systemic administration. Regardless of the cell type and whether systemic or regional administrations of AIDD systems are viable, the newly designed adenoviral vector system and the mechanisms of drug delivery offered by AIDD, such as enhancement of drug transport through a permeable apoptotic cell membrane, remain unique and warrant further preclinical evaluations to assess the effectiveness of drug delivery.
